Marcus Schindler

EVP for Research and Early Development & Chief Scientific Officer at Novo Nordisk


Professor Marcus Schindler, PhD, is Senior Vice President and Head of Global Drug Discovery at Novo Nordisk A/S. He is accountable for all of Novo Nordisk’s Research activities across all of Novo Nordisk’s Therapeutic Areas (Diabetes, Obesity, NASH, Rare blood disorders, Rare endocrine disorders, Chronic Kidney and Cardiovascular Disease). In addition, he is responsible for identifying, establishing and maintaining all external partnerships and collaborations up to and including Clinical Proof of Concept within these therapy areas. He also represents Novo Nordisk as Supervisory Board Member of Innate Pharma (France).

Marcus has close to 20 years of experience in leadership roles in the pharmaceutical industry, working both in international large pharma and biotechnology companies including Astra Zeneca (Sweden), Boehringer Ingelheim (Germany) and (OSI) Prosidion (UK).

Marcus Schindler received his PhD in Pharmacology from the University of Cambridge and holds a position as adjunct Professor of Pharmacology at the University of Gothenburg. He has co-/authored 50+ peerreviewed research papers and is an inventor of 25 international patent applications



  • EVP for Research and Early Development & Chief Scientific Officer

    March 1, 2021 - present

  • Senior Vice President, Head of Global Drug Discovery

    January, 2018

View in org chart